The drug manufacturer Dr. Reddy’s Laboratories has launched Posaconazole Sustained Release Tablets 100 mg in the United States
The product is an azole antifungal and therapeutic generic equivalent to Noxafil (posaconazole) delayed-release tablets, 100 mg, and was launched after US Food and Drug Administration approval, the company said. It is indicated for the prophylaxis of certain fungal infections in severely immunocompromised patients.
Noxafil brand and generic had US sales of approximately $140.8 million MAT for the trailing 12 months to February 2022, said Dr. Reddy’s citing IQVIA numbers.
